Pharmacological action and clinical results of Omarigliptin (MARIZEV<sup>®</sup> tablet), a novel dipeptidyl peptidase-4 inhibitor for once-weekly treatment of Type 2 diabetes
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.